Filing Flows

Filing Flows › Health Care › Abeona Therapeutics (ABEO)

Abeona Therapeutics (ABEO) earnings and revenue breakdown

Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Abeona Therapeutics (ABEO) Q2 2026 earnings results →

Q2 2026 Revenue up 2745% year over year to $11.4M · 177¢ of every $1 of revenue lost · operating margin -120.0%

Abeona Therapeutics made $11.4M in Q2 2026 (28× Y/Y). Operating margin -120.0%, net loss $20.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.

Revenue$11.4M
Year over year28×
Operating margin-120.0%
Net earnings−$20.2M
Operating cash flow−$17.5M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $11.4M in Q2 2026, up 2745% year over year and up 31% from the previous quarter.

Operating costs exceeded revenue by $13.7M, an operating margin of -120.0%. Total costs grew 8% against revenue growth of 2745%. The quarter ended with a net loss of $20.2M, wider than the previous quarter's $17.1M loss.

Operating cash flow was −$17.5M. Non-cash charges added back $665K of depreciation and amortization and $3.4M of share-based compensation. Working capital and other items used $1.3M. Capital expenditures of $479K exceeded it, leaving free cash flow of −$18.0M.

Quarterly history

Abeona Therapeutics revenue by quarterAbeona Therapeutics revenue by quarter$400KQ2 2025$5.4MQ4 2025$8.7MQ1 2026$11.4MQ2 2026
Abeona Therapeutics net earnings by quarterAbeona Therapeutics net earnings by quarter$109MQ2 2025−$20.5MQ4 2025−$17.1MQ1 2026−$20.2MQ2 2026
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q2 202610-QAug 13, 2026$11.4M28×-120.0%−$20.2M−$17.5M
Q1 202610-QMay 13, 2026$8.7M—-264.1%−$17.1M−$19.8M
Q4 202510-KMar 17, 2026$5.4M—-422.7%−$20.5M−$18.0M
Q2 202510-QAug 14, 2025$400K—n/m$109M−$18.8M

Charts

Abeona Therapeutics: revenue growth, year over year and quarter over quarterAbeona Therapeutics: revenue growth, year over year and quarter over quarterY/YQ/Q+400%Q4 2025+61%Q1 2026+400%+31%Q2 2026
Latest (Q2 2026): Y/Y +400%, Q/Q +31%.
Abeona Therapeutics: where the cash came from (+) and went (−), TTM to Q2 2026Abeona Therapeutics: where the cash came from (+) and went (−), TTM to Q2 2026Cash drawn (+) / kept (−)$108MOperating cash flow−$76.4MOther investing−$29.3MCapital spending−$5.1MOther financing$3.2M
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Abeona Therapeutics: profit against cash, quarter by quarterAbeona Therapeutics: profit against cash, quarter by quarterNet incomeOperating cash flow−$30.3M−$12.2MQ3 2024−$9.3M−$16.6MQ4 2024−$12.0M−$18.4MQ1 2025$109M−$18.8MQ2 2025−$5.2M−$21.2MQ3 2025−$20.5M−$18.0MQ4 2025−$17.1M−$19.8MQ1 2026−$20.2M−$17.5MQ2 2026
Latest (Q2 2026): Net income −$20.2M, Operating cash flow −$17.5M.
Abeona Therapeutics: diluted shares by fiscal year (split-adjusted)Abeona Therapeutics: diluted shares by fiscal year (split-adjusted)556MFY2020591MFY202147MFY202243MFY202341MFY202466MFY2025
-88.1% since FY2020: buybacks shrank the count; earlier years scaled for the 2-for-1 split before FY2024, 3-for-1 split before FY2023.
Abeona Therapeutics: long-term debt falling due (FY2024)Abeona Therapeutics: long-term debt falling due (FY2024)$5.9M2025$8.9M2026$5.2M2027
Cash $23.4M, short-term investments $74.4M, long-term debt $19.0M at 2024-12-31.
Abeona Therapeutics in its industry: growth against margin (225 companies, SIC 2834)Abeona Therapeutics in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYABTREGNTEVAVTRSVRTXBHCZTSONCOGNALNYELANJAZZBMRNPRGOAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLPAHCSRPTPTCTINDVBBIOACADCORTPBHANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVIORGONUVBLFVNSIGAKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXELTPSEPNVRDNLFCRCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIAYTUFHTXENTATNXPOCULASMBWVEAPMDBFRISTOKLXRXCAPRIDYANKTRZOMDFINBPJANXSBFMGOSSETSTRCUSCPIXLIFDCUEAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSVTGNROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBIRDOVIDSPRBXBIOPRTAMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLCOYASCYXBFRGSXTPBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMABEO (+300%, -100%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Abeona Therapeutics

Abeona Therapeutics Inc., a Delaware corporation (together with our subsidiaries, “we,” “our,” “Abeona” or the “Company”), is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. On April 28, 2025, the U.S. Food and Drug Administration (“FDA”) approved ZEVASKYN ® (prademagene zamikeracel) gene-modified cellular sheets, also known as ZEVASKYN ® , as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (“RDEB”), a serious and debilitating genetic skin disease. There is no cure for RDEB, and ZEVASKYN ® is the only FDA-approved product to treat RDEB wounds with a single surgical application. ZEVASKYN ® was granted Orphan Drug and Rare Pediatric Disease designations by the FDA

In its own words, from its 10-K, filed Mar 17, 2026.

Abeona Therapeutics against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: 28× against the peers' median +10%. Operating margin: -120.0% against the peers' median 20.4%.

CompanyQuarterRevenueY/YOp. margin
ABEO Abeona TherapeuticsQ2 2026$11.4M28×-120.0%
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%

Source: Abeona Therapeutics 10-Q on SEC EDGAR · CIK 318306 · Pharmaceutical Preparations

13F: who owns ABEO and who is buying

Largest holders of ABEO (13F)Largest holders of ABEO (13F)Nantahala Capital Management, LLC$63.5MBlackRock$20.7MCable Car Capital, LP$18.6MAigh Capital Management LLC$15.2MVanguard Group$14.5MVanguard Capital Management LLC$13.7MGeode Capital Management, LLC$7.8MKennedy Capital Management LLC$7.7MGoldman Sachs Group$7.6MState Street$6.4M
Funds' net buying of ABEO by quarter (13F)Funds' net buying of ABEO by quarter (13F)−$32.1M2024-09$3.0M2024-12−$6.2M2025-03$22.4M2025-06$6.4M2025-09$18.2M2025-12−$273K2026-03$17.7M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on ABEO

History

Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q2 2025 results

Compare ABEO with

中文版：Abeona Therapeutics（ABEO）财报

Español · Français